Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011059 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Anya Bauer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus, HIV Infections, HIV-1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIAID NIH HHS, NIMH NIH HHS, NIH HHS.
Abstract (Originalsprache)
Transmitted/founder (TF) simian-human immunodeficiency viruses (SHIVs) express HIV-1 envelopes modified at position 375 to efficiently infect rhesus macaques while preserving authentic HIV-1 Env biology. SHIV.C.CH505 is an extensively characterized virus encoding the TF HIV-1 Env CH505 mutated at position 375 shown to recapitulate key features of HIV-1 immunobiology, including CCR5-tropism, a tier 2 neutralization profile, reproducible early viral kinetics, and authentic immune responses. SHIV.C.CH505 is used frequently in nonhuman primate studies of HIV, but viral loads after months of infection are variable and typically lower than those in people living with HIV. We hypothesized that additional mutations besides Δ375 might further enhance virus fitness without compromising essential components of CH505 Env biology. From sequence analysis of SHIV.C.CH505-infected macaques across multiple experiments, we identified a signature of envelope mutations associated with higher viremia. We then used short-term in vivo mutational selection and competition to identify a minimally adapted SHIV.C.CH505 with just five amino acid changes that substantially improve virus replication fitness in macaques. Next, we validated the performance of the adapted SHIV in vitro and in vivo and identified the mechanistic contributions of selected mutations. In vitro , the adapted SHIV shows improved virus entry, enhanced replication on primary rhesus cells, and preserved neutralization profiles. In vivo , the minimally adapted virus rapidly outcompetes the parental SHIV with an estimated growth advantage of 0.14 days- 1 and persists through suppressive antiretroviral therapy to rebound at treatment interruption. Here, we report the successful generation of a well-characterized, minimally adapted virus, termed SHIV.C.CH505.v2, with enhanced replication fitness and preserved native Env properties that can serve as a new reagent for NHP studies of HIV-1 transmission, pathogenesis, and cure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
- Kirby Institute, University of New South Wales, Sydney, Australia.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, United States of America.
- Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Maryland, United States of America.
- AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
- Department of Pathology and Laboratory Medicine, Tulane School of Medicine, New Orleans, Louisiana, United States of America.
ORCID-Profile: Katharine J Bar
Förderung
- NIAID NIH HHS
- NIMH NIH HHS
- NIH HHS
- Office of AIDS Research
- Beat HIV Collaboratory
- Collaboratory of AIDS Researchers for Eradication
Zitieren
APA
Bauer, A., Lindemuth, E., Marino, F. E., Krause, R., Joy, J., Docken, S. S., Mallick, S., McCormick, K., Holt, C., Georgiev, I., Felber, B., Keele, B. F., Veazey, R., Davenport, M. P., Li, H., Shaw, G. M., & Bar, K. J. (2023). Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011059
Vancouver
Bauer A, Lindemuth E, Marino FE, Krause R, Joy J, Docken SS, et al. Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011059
BibTeX
@article{Bauer2023,
author = {Bauer, Anya and Lindemuth, Emily and Marino, Francesco Elia and Krause, Ryan and Joy, Jaimy and Docken, Steffen S and Mallick, Suvadip and McCormick, Kevin and Holt, Clinton and Georgiev, Ivelin and Felber, Barbara and Keele, Brandon F and Veazey, Ronald and Davenport, Miles P and Li, Hui and Shaw, George M and Bar, Katharine J},
title = {Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011059}
}
EUVIMED